Curated News
By: NewsRamp Editorial Staff
June 09, 2025
Leksum & SLU Pioneer Unique Muscle Research Lab for ICU Myopathies
TLDR
- Leksum LLC's partnership with SLU establishes a unique muscle research lab, offering unparalleled insights into ICU-related muscle myopathies, positioning Leksum as a leader in advanced biologic therapies.
- The lab utilizes a unique experimental ICU model to study long-term muscle mass and function loss, enabling detailed mechanistic and intervention studies under ICU conditions.
- This collaboration aims to develop therapies for muscle myopathies, improving the quality of life for millions of ICU patients worldwide by addressing critical illness myopathy.
- Leksum and SLU's groundbreaking lab can replicate long-term ICU conditions, a world-first, paving the way for innovative treatments in muscle myopathy research.
Impact - Why it Matters
This collaboration represents a significant leap forward in understanding and treating muscle myopathies, particularly those associated with long-term ICU care. The research has the potential to improve the quality of life for millions of patients worldwide by addressing the critical issue of muscle loss under mechanical ventilation and immobilization. It also opens new avenues for treating other muscle-related conditions, offering hope for better therapeutic strategies.
Summary
In a groundbreaking collaboration, Leksum LLC and the Department of Clinical Sciences at SLU, Uppsala, Sweden, have established a unique muscle research lab. This facility, led by Lars Larsson, MD/PhD, Leksum's Chief Scientific Officer, specializes in long-term mechanistic and intervention studies of muscle myopathies under ICU conditions, a first of its kind. The lab's ability to replicate long-term survival without the limitation of early mortality marks a significant advancement in muscle science research. This partnership aims to develop therapies for acquired muscle myopathies, with a focus on conditions resulting from mechanical ventilation and immobilization in ICUs.
Professor Larsson highlights the importance of this collaboration, noting its potential to benefit millions of patients annually by providing both prophylactic and therapeutic solutions. Leksum's research extends beyond ICU-related myopathies to include sarcopenia, cancer cachexia, and muscle loss due to weight-loss drugs, positioning the company at the forefront of muscle health innovation. SLU's role in this partnership underscores its commitment to sustainable societal development through education, research, and environmental monitoring.
Source Statement
This curated news summary relied on content disributed by Reportable. Read the original source here, Leksum & SLU Pioneer Unique Muscle Research Lab for ICU Myopathies
